HUTCHMED (HCM) CEO Su Wei-guo reports major share and option stakes

Rhea-AI Filing Summary

HUTCHMED (China) Ltd director and CEO/CSO Su Wei-guo filed an initial ownership report showing a sizeable equity stake. He holds share options over 1,000,000 ordinary shares expiring in 2027 and another 1,000,000 ordinary shares expiring in 2028, plus additional options over American depositary shares with exercise prices between $22.09 and $35.21 per ADS and expirations from 2030 to 2031. Further options cover 1,405,767 ordinary shares expiring in 2034 and 1,493,435 ordinary shares expiring in 2035. He also directly owns 3,563,905 ordinary shares and 237,063 American depositary shares, and has indirect Long Term Incentive Plan awards over 39,862 and 169,977 ordinary shares held by a plan trustee. Each American depositary share represents 5 ordinary shares.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Su Wei-guo

(Last) (First) (Middle)

C/O 48TH FLOOR, CHEUNG KONG CENTER, 2

QUEEN'S ROAD CENTRAL

(Street)

HONG KONG K3 00000

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2026

3. Issuer Name and Ticker or Trading Symbol
HUTCHMED (China) Ltd [ HCM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and CSO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
ordinary shares	3,563,905	D
American depositary shares(1)	237,063	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share option (right to buy)(2)	03/27/2017	03/26/2027	ordinary shares	1,000,000	(3)	D
Share option (right to buy)(2)	03/19/2018	03/18/2028	ordinary shares	1,000,000	(4)	D
Share option (right to buy)(2)	04/28/2020	04/27/2030	American depositary shares	157,940	$22.09(5)	D
Share option (right to buy)(2)	12/14/2020	12/13/2030	American depositary shares	3,792	$29(5)	D
Share option (right to buy)(2)	03/26/2021	03/25/2031	American depositary shares	56,480	$27.94(5)	D
Share option (right to buy)(2)	12/14/2021	12/13/2031	American depositary shares	4,986	$35.21(5)	D
Share option (right to buy)(6)	08/05/2024	08/04/2034	ordinary shares	1,405,767	(7)	D
Share option (right to buy)(6)	06/09/2025	06/08/2035	ordinary shares	1,493,435	(8)	D
Long Term Incentive Plan awards granted on 03/13/2024	(9)	(9)	ordinary shares	39,862	(9)	I	Held by Long Term Incentive Plan trustee
Long Term Incentive Plan awards granted on 08/05/2024	(10)	(10)	ordinary shares	169,977	(10)	I	Held by Long Term Incentive Plan trustee

Explanation of Responses:

1. Each American depositary share represents 5 ordinary shares.

2. The share options granted are exercisable subject to, amongst other relevant vesting criteria, the vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the date of grant of share options.

3. The exercise price for the share option is GBP3.105 per ordinary share.

4. The exercise price for the share option is GBP4.974 per ordinary share.

5. The exercise price for the share option is denominated in United States dollar per American depositary share.

6. The exercise of the share options granted is conditional upon the fulfilment of performance targets prescribed by the Board for the relevant performance periods (2023-2025, 2024-2026 and 2025-2027), as set out in the respective grant letters. For each grant, the number of share options that may become exercisable will be determined on the date of announcement of the annal results of the Company for the final financial year of the applicable performance period (i.e. the annual results announcements for the financial years ending December 31, 2025, 2026 and 2027, respectively). Vesting will occur two business days after the relevant results announcement. Any share options in respect of which the applicable performance targets are not met will lapse accordingly.

7. The exercise price for the share option is HKD29.200 per ordinary share.

8. The exercise price for the share option is HKD25.500 per ordinary share.

9. 25% of Long Term Incentive Plan Awards vesting on each of March 13, 2025, March 13, 2026, March 13, 2027 and March 13, 2028.

10. All Long Term Incentive Plan Awards will vest in 2027, three weeks after the date of completion of the share purchase for the awards for the financial year ending December 31, 2026.

	/s/ Su Wei-guo	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Su Wei-guo’s Form 3 filing show for HUTCHMED (HCM)?

The Form 3 shows CEO/CSO Su Wei-guo’s initial ownership in HUTCHMED, including direct ordinary shares, American depositary shares, multiple share option grants, and Long Term Incentive Plan awards held via a trustee, outlining his total reported equity exposure to the company.

How many HUTCHMED ordinary shares does Su Wei-guo hold directly?

Su Wei-guo is reported as directly holding 3,563,905 ordinary shares of HUTCHMED. This direct stake is separate from his options and Long Term Incentive Plan awards, providing a substantial base ownership position alongside his various derivative and incentive holdings in the company.

What American depositary share holdings are reported for Su Wei-guo in HCM?

The filing reports Su Wei-guo directly holding 237,063 American depositary shares of HUTCHMED. Each American depositary share represents 5 ordinary shares, giving him additional exposure beyond his directly held ordinary shares and his various outstanding share option awards.

What key share option positions does Su Wei-guo have in HUTCHMED (HCM)?

Su Wei-guo holds share options over 1,000,000 ordinary shares expiring in 2027 and another 1,000,000 ordinary shares expiring in 2028. He also holds further options over ordinary shares and American depositary shares with expirations extending out to 2035, subject to vesting and performance conditions.

How do performance conditions affect Su Wei-guo’s HUTCHMED share options?

The filing explains that exercise of certain share options depends on performance targets for 2023-2025, 2024-2026 and 2025-2027. The number of options that become exercisable will be determined around annual results announcements for the final year of each applicable performance period.

What Long Term Incentive Plan awards linked to HUTCHMED shares are reported?

Su Wei-guo has indirect Long Term Incentive Plan awards over 39,862 ordinary shares from March 13, 2024 grants and 169,977 ordinary shares from August 5, 2024 grants. These awards are held by a plan trustee and vest according to specified multi-year schedules described in the filing’s footnotes.